Entity
  • FundaMental Pharma

    Created in 2016


  • Up & running (A)
    Existing signals show a regular activity
  • Social networks

    829
  • Activities

  • Technologies

  • Entity types

  • Location

    Im Neuenheimer Feld 582, 69120 Heidelberg, Germany

    Heidelberg

    Germany

  • Employees

    Scale: 2-10

    Estimated: 11

  • Engaged catalyst

    0
    0 0
  • Added in Motherbase

    1 year ago
Description
  • Value proposition

    We Fight Neurodegeneration

    FundaMental Pharma is engaged in pioneering research around a breakthrough molecular mechanism that allows to safely counteract glutamate neurotoxicity (also known as excitotoxicity) by specifically targeting the interface between NMDA receptors and TRPM4 channels with small molecule TwinF interface inhibitors (Yan et al., Science 2020). TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration. Our initial focus is on amyotrophic lateral sclerosis (ALS). The applicability of our molecules extends to a range of neurogenerative disorders including Alzheimer’s disease (AD).

Catalyst interactions
Catalyst TypeTweets Articles
No interactions
Social network dynamics
Similar entities
BETA
Loading...
Loading...